A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. [electronic resource]
Producer: 20160209Description: 898-904 p. digitalISSN:- 1592-8721
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Benzamides -- administration & dosage
- Blast Crisis -- drug therapy
- Drug Administration Schedule
- Febrile Neutropenia -- chemically induced
- Female
- Fusion Proteins, bcr-abl -- genetics
- Humans
- Imatinib Mesylate -- administration & dosage
- Leukemia, Myeloid, Accelerated Phase -- drug therapy
- Male
- Middle Aged
- Mucositis -- chemically induced
- Mutation
- Philadelphia Chromosome
- Protein Kinase Inhibitors -- administration & dosage
- Pyrazoles -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.